PHIO
Phio Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PHIO
Phio Pharmaceuticals Corp.
A clinical stage biotechnology company that develops therapeutics based on RNA interference
11 Apex Drive, Suite 300A PMB 2006, Marlborough, Massachusetts 01752
--
Phio Pharmaceuticals Corp. was incorporated in Delaware on September 8, 2011 as a wholly-owned subsidiary of Galena in preparation for the company's planned spin-off from Galena, which was completed on April 27, 2012. Since that date, the company has operated as an independent public company. Is a biotechnology company focused on the discovery, development and commercialization of innovative therapies based on the company's proprietary next-generation RNA interference (" RNAi ") platform. Therapeutic drugs using RNAi have great promise due to their ability to "silence" or down-regulate the expression of specific genes. Before September 8, 2011, the Company's business operated as an unincorporated division within Galena Biopharma, Inc. (" Galena "or the" Parent Company "), the former parent company of the Company.
Company Financials
EPS
PHIO has released its 2025 Q2 earnings. EPS was reported at -0.45, versus the expected -0.36, missing expectations. The chart below visualizes how PHIO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
